Sol-Gel Technologies Ltd. Overview
SLGL market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
SLGL price chart · 1M
- O
- 66.56
- H
- 66.56
- L
- 66.56
- C
- 66.56
- Vol
- 0.000000
Daily history from Feb 1, 2018
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $66.56
- Previous Close
- $66.56
- Day High
- $66.56
- Day Low
- $66.56
- 52 Week High
- $90.00
- 52 Week Low
- $31.50
- 7 Day Return
- -2.42%
- 30 Day Return
- -13.22%
- 90 Day Return
- -19.61%
- 1 Year Return
- +85.35%
- Daily Notional Volume
- $0 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -910.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $28.81 – $97.97 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $210.7M · P/B 5.15 · P/S 117.41.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
7 captured
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga ·
SolGel Technologies (SLGL) Upgraded to Buy: Here's WhyZacks Investment Research ·